-
Low disease activity was observed after a mean duration of 80
consecutive days off-treatment following success with VTAMA cream,
with a mean weekly Peak Pruritus Numerical Rating Scale (PP-NRS) score
of 2.9 at the end of the treatment-free interval
-
Data presented as late breaker at 2025 American Academy of
Dermatology (AAD) Annual Meeting
JERSEY CITY, N.J.--(BUSINESS WIRE)--
Organon (NYSE: OGN), a global healthcare company with a focus on women’s
health, today announced results from an analysis of the Phase 3 ADORING 3
open-label, long-term extension study evaluating VTAMA®
(tapinarof) cream, 1% once daily in adults and children 2 years of age and
older with atopic dermatitis (AD), also known as eczema. The findings
demonstrate that AD disease activity remained mild in patients who had
achieved treatment success and subsequently entered a treatment-free
interval lasting on average 80 days. These results were presented during a
late-breaking research session today at the 2025 American Academy of
Dermatology (AAD) Annual Meeting.
“For patients with atopic dermatitis, the benefits of many topical
treatments are often short-lived, and for some patients, their disease
rapidly reappears after taking a break from topical treatments,” said
Jonathan Silverberg, M.D., Ph.D., M.P.H., George Washington University
School of Medicine and Health Sciences. “As a physician, I’m encouraged that
at the end of a break from treatment with VTAMA cream, patients’ AD remained
mild. I’m excited to see these data support the use of VTAMA cream to
potentially provide lasting results for itch, which is the universal and
most burdensome symptom of AD.”
ADORING 3 (N=728) was a 48-week open-label, long-term extension study that
enrolled eligible patients from the pivotal Phase 3 ADORING 1 and ADORING 2
trials, patients from a 4-week maximal usage pharmacokinetics study, and
VTAMA cream-naive patients 2-17 years of age with either mild, moderate, or
severe AD that did not meet inclusion criteria in ADORING 1 and ADORING 2.
In ADORING 3, those who entered with or achieved completely clear skin
(n=378), defined as a validated Investigator Global Assessment for AD
(vIGA-AD
™
) score of 0, stopped using VTAMA cream and were assessed for
maintenance of vIGA-AD of 0 (clear) or 1 (almost clear) off-treatment.
Patients whose AD returned to a vIGA-AD of 2 or higher (mild or above) were
retreated with VTAMA cream until complete disease clearance was achieved
again or until study completion.
The new results demonstrate that, at the end of the first treatment-free
interval, which lasted an average of 79.8 consecutive days, 84% of patients
had a vIGA-AD score of 2 (mild). Itch, which was assessed with the patient
reported Peak Pruritus Numerical Rating Scale (PP-NRS) score ranging from 0
to 10, remained low with a mean weekly PP-NRS score of 2.9. The mean Eczema
Area and Severity Index (EASI) score was 3.4, indicating mild disease.
The most frequent treatment-emergent adverse events (TEAEs) in ADORING 3
included folliculitis (12.1%), nasopharyngitis (6.9%), and upper respiratory
tract infection (6.9%); trial discontinuations due to TEAEs were low (2.6%).
Adverse events of special interests including follicular events, contact
dermatitis, and headache were mostly mild or moderate and associated with
low discontinuation rates (1.0%, 0.4%, and 0%, respectively).
“These data reinforce the efficacy of VTAMA cream in atopic dermatitis,
including the durability of effect among patients in the study, including
children as young as two years old,” said Juan Camilo Arjona Ferreira, M.D.,
Head of Research and Development and Chief Medical Officer at Organon
.
“Knowing the profound impact that atopic dermatitis can have on the lives of
patients, and oftentimes their caregivers, the possibility to receive over
two months of relief without needing to reapply treatment is meaningful and
speaks to our mission of creating a healthier every day.”
In December 2024, the U.S. Food and Drug Administration (FDA) approved VTAMA
(tapinarof) cream, 1% for the topical treatment of AD in adults and
pediatric patients 2 years of age and older. VTAMA cream was also approved
by the FDA on May 24, 2022, for the topical treatment of mild, moderate, and
severe plaque psoriasis in adults.
IMPORTANT SAFETY INFORMATION
Indications: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon
receptor agonist indicated for:
- the topical treatment of plaque psoriasis in adults.
-
the topical treatment of atopic dermatitis in adults and pediatric
patients 2 years of age and older.
Adverse Events: In plaque psoriasis, the most common adverse
reactions (incidence ≥1%) were: red raised bumps around the hair pores
(folliculitis); pain or swelling in the nose and throat (nasopharyngitis);
skin rash or irritation, including itching and redness, peeling, burning, or
stinging (contact dermatitis); headache; itching (pruritus); and flu
(influenza).
Adverse Events: In atopic dermatitis, the most common adverse
reactions (incidence ≥1%) were: upper respiratory tract infection; red
raised bumps around the hair pores (folliculitis); lower respiratory tract
infection; headache; asthma; vomiting; ear infection; pain in extremity; and
stomach-area (abdominal) pain.
You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit
www.fda.gov/medwatch
or call 1-800-FDA-1088.
Before prescribing VTAMA cream, please read the full
Prescribing Information and Patient Information.
For more information about VTAMA (tapinarof) cream, 1%, visit
www.vtamahcp.com.
About ADORING
ADORING is the Phase 3 AD clinical development program for VTAMA (tapinarof)
cream, 1%, which consists of ADORING 1 (NCT05014568) and ADORING 2
(NCT05032859), as well as ADORING 3 (NCT05142774), a 48-week open-label,
long-term extension study.
About Atopic Dermatitis
AD, commonly referred to as eczema, is one of the most prevalent
inflammatory skin diseases, affecting over 26 million people in the U.S.
alone and up to 10% of adults worldwide.1,2,3 AD occurs most
frequently in children, affecting up to 20% worldwide.2,3 The
disease results in itchy, red, swollen, and cracked skin, often on the folds
of the arms, back of the knees, hands, face, and neck.1 Itching
is an especially bothersome symptom for those with AD, and tends to worsen
at night.2,4,5
About Organon
Organon is an independent global healthcare company with a mission to help
improve the health of women throughout their lives. Organon’s diverse
portfolio offers over 70 medicines and products in women’s health,
biosimilars, and a large franchise of established medicines across a range
of therapeutic areas. In addition to Organon’s current products, the company
invests in innovative solutions and research to drive future growth
opportunities in women’s health and biosimilars. Organon is also pursuing
opportunities to collaborate with biopharmaceutical partners and innovators
who look to commercialize their products by leveraging Organon’s scale and
agile presence in fast growing international markets.
Organon has geographic scope with significant reach, world-class commercial
capabilities, and approximately 10,000 employees with headquarters located
in Jersey City, New Jersey.
For more information, visit
http://www.organon.com
and connect with us on
LinkedIn,
Instagram,
X (formerly known as Twitter)
and
Facebook.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements about the potential uses and
efficacy of VTAMA cream. Forward-looking statements may be identified by
words such as “potentially,” “opportunity,” “continue,” “will,” “pursuing,”
“future,” or words of similar meaning. These statements are based upon the
current beliefs and expectations of the company’s management and are subject
to significant risks and uncertainties. If underlying assumptions prove
inaccurate, or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, an inability to
execute on our business development strategy; weakening of economic
conditions that could adversely affect the level of demand for VTAMA;
pricing pressures globally, including rules and practices of managed care
groups, judicial decisions and governmental laws and regulations related to
Medicare, Medicaid and health care reform, pharmaceutical reimbursement and
pricing in general; an inability to fully execute on our product development
and commercialization plans; governmental initiatives that adversely impact
Organon’s marketing activities; the failure of any supplier to provide
substances, materials, or services as agreed; the increased cost of supply,
manufacturing, packaging, and operations; difficulties developing and
sustaining relationships with commercial counterparties; competition from
generic products as our products lose patent protection; disruptions at the
U.S. Food and Drug Administration, the U.S. Securities and Exchange
Commission (the “SEC”) and other U.S. and comparable foreign government
agencies; and the failure by us or our third party collaborators and/or
their suppliers to fulfill our or their regulatory or quality obligations.
The company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ materially
from those described in the forward-looking statements can be found in the
company’s filings with the SEC, including the company’s most recent Annual
Report on Form 10-K and subsequent SEC filings, available at the SEC’s
Internet site (www.sec.gov).
© 2025 Organon group of companies. All rights reserved. vIGA-AD is the
trademark of Eli Lilly and Co. US-CORP-2500009
1
Atopic Dermatitis. NIAMS website. Available at:
https://www.niams.nih.gov/health-topics/atopic-dermatitis. Accessed March 2025.
2
Eczema Stats. NEA website. Available at:
https://nationaleczema.org/research/eczema-facts/. Accessed March 2025.
3
Global Report on Atopic Dermatitis 2022. Eczema Council website. Available
at:
https://www.eczemacouncil.org/assets/docs/global-report-on-atopic-dermatitis-2022.pdf. Accessed March 2025.
4
Beckman L, Hagquist C, Svensson Å, Langan SM, Von Kobyletzki L. Relationship
between eczema and self-reported difficulties keeping up with school
education: A cross-sectional study.
Acta Derm Venereol.
June 2023;103:5268.
5
Cheng BT, Patel MS, Xu M, et al. Timing of itch among children with atopic
dermatitis.
Ann Allergy Asthma Immunol
. February 2022;128(5):603–605.
Source: Organon & Co.